1. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
- Author
-
Xuan Hoan, Nghiem, Thi Minh Huyen, Pham, Dinh Tung, Bui, Phuong Giang, Dao, Tat Trung, Ngo, Tien Sy, Bui, Thi Tuan, Nguyen, Thi Ngoc Dung, Dang, Reddy Pallerla, Srinivas, Velavan, Thirumalaisamy P., Hong Bang, Mai, and Huu Song, Le
- Subjects
- *
HEPATITIS B , *CHRONIC hepatitis B , *PROGRAMMED cell death 1 receptors , *DISEASE progression , *LIVER diseases , *HEPATITIS , *PROGRAMMED death-ligand 1 - Abstract
• Activation of PD-1/PD-L1 signaling pathway is considered to cause HBV-specific CD8+T cell exhaustion in chronic HBV infection. • Increased expression of PD-L1 involves in various health conditions, including infectious diseases, chronic inflammations, cancers. • The missense variant PD-L1 rs2297136 is associated with HBV infection susceptibility and liver disease progression. • Plasma sPD-L1 correlated with liver inflammation and associated with clinical outcomes in HBV infected patients. Soluble molecules of programmed death ligand 1 (sPD-L1) are known to modulate T-cell depletion, an important mechanism of hepatitis B virus (HBV) persistence and liver disease progression. In addition, PD-L1 polymorphisms in the 3′-UTR can influence PD-L1 expression and have been associated with cancer risk, although not definitively. The purpose of this study was to investigate the association of PD-L1 polymorphisms and circulating levels of sPD-L1 in HBV infection and live disease progression. In this study, five hundred fifty-one HBV infected patients of the three clinically well-defined subgroups chronic hepatitis B (CHB, n = 186), liver cirrhosis (LC, n = 142) and hepatocellular carcinoma (HCC, n = 223) and 240 healthy individuals (HC) were enrolled. PD-L1 polymorphisms (rs2297136 and rs4143815) were genotyped by in-house validated ARMS assays. Logistic regression models were applied in order to determine the association of PD-L1 polymorphisms with HBV infection as well as with progression of related liver diseases. Plasma sPD-L1 levels were quantified by ELISA assays. The PD-L1 rs2297136 AA genotype was associated with HBV infection susceptibility (HBV vs. HC: OR = 1.6; 95%CI = 1.1–2.3; p = 0.0087) and disease progression (LC vs. CHB: OR = 1.8; 95%CI = 1.1–2.9; p = 0.018). Whereas, the rs2297136 GG genotype was a protective factor for HCC development. Plasma sPD-L1 levels were significantly high in HBV patients (p < 0.0001) and higher in the LC followed by CHB and HCC groups. High sPD-L1 levels correlated with increased liver enzymes and with advanced liver disease progression (Child-pugh C > B > A, p < 0.0001) and BCLC classification (BCLC D > C > B > A, p = 0.031). We could, for the first time, conclude that PD-L1 rs2297136 polymorphism and plasma sPD-L1 protein levels associate with HBV infection and HBV-related liver disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF